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of Thrombocythemia
Bela Balint, Mirjana Pavlovic and Milena Todorovic
Abstract
The objective of this chapter is to provide a systematic overview of current 
knowledge regarding therapeutic apheresis—primarily therapeutic plateletapheresis 
(TP)—and to summarize evidence-based practical approaches related to cytapher-
esis treatment of “hyperthrombocytosis” or “extreme thrombocytosis” (ETC). Our 
results of platelet (Plt) quantitative/qualitative analyses and evaluation of efficacy 
of apheresis systems/devices—on the basis of Plt removal and in vivo Plt deple-
tion—will be presented. Our preclinical researches confirmed that in Plt concen-
trates, the initial ratio of discoid shapes was 70%, spherical 20%, and less valuable 
(dendritic/balloonized) shapes 10%—with morphological score of platelets (MSP 
= 300–400). After storage, the ratio of discoid and spherical shapes was decreased, 
while the less valuable ones progressively increased (MSP = 200). Electron micros-
copy has shown discoid shapes with typical ultrastructural properties. Spherical 
shapes with reduced electron density and peripheral location of granules/organelles 
were detected. Also, dendritic shapes with cytoskeletal “rearrangement,” membrane 
system integrity damages, and pseudopodia formations were documented. Our 
clinical study demonstrated that TP was useful in ETC treatment and should help 
prevention of “thrombo-hemorrhagic” events—until chemotherapy, antiplatelet 
drugs, and other medication take effect. During TP treatment, Plt count and 
morphology/ultrastructure were examined. Plt functions by multiplate analyzer 
were evaluated. We concluded that intensive TP was an effective, safe, and rapid 
cytoreductive treatment for ET.
Keywords: platelet, morphology-ultrastructure, thrombocythemia, apheresis, 
plateletapheresis
1. Introduction
Besides supportive treatment using whole blood, red blood cell (RBC), platelet 
(Plt), and plasma transfusions, hemotherapy, in an extensive viewpoint, involves also 
performing different apheresis procedures to remove or replace altered or overpro-
duced and accumulated blood constituents (cell and plasma contents, pathogens, 
metabolic products, etc.). Hemotherapy also involves collection and ex vivo manipu-
lation of stem cells (SCs) with a goal of reconstitution of hematopoiesis in performing 
conventional transplantations and for use in the fields of regenerative medicine.
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Thus, the basic aim of hemotherapy is reconstitution and maintenance of a 
“hemobiological” (hematological, immunological, hemorheological) equilibrium 
or homeostasis by the recovery of lacking blood components, as well as through the 
use of apheresis and other “hemo-modifying” procedures. By doing this, the circu-
lating blood volume is reestablished, but also the “blood oxiform function” (capac-
ity for oxygen binding/transport), hemostasis, and activity of “immune response 
mediators” are restored. The rationalized and well-timed hemotherapy is contribut-
ing to increased survival of patients with some “life-threatening” conditions.
During supportive hemotherapy of patients with potential beneficial clinical 
response, it is essential to perform the most rational and “well-timed” interven-
tion in the most appropriate manner—that is determining the most efficient and 
approachable therapeutic procedures and techniques. Also, it is imperative to opti-
mize specific indications of blood component therapy with rationalized thresholds.
Also, the most sensitive point during planning and performing therapeutic 
apheresis (TAph), especially cytapheresis, is determination of the most optimal 
approach to the treatment or, even better, the “time-frequency-intensity con-
tinuum” of the procedure. The introduction of cytapheresis treatment requires 
determination of total blood cell quantity within the organism, sometimes even 
determination of the ratio between cells in intravascular versus extravascular space. 
The evaluation of hematopoietic potential and the reserve in bone marrow, as well 
as calculation of the intensity of cell production (“cytogenesis-kinetics”) in the 
peri-apheresis period, is important too.
Before evaluation of results of TP in the treatment of our patients, several 
principles and standards of the apheresis treatment will be presented. Thus, this 
chapter will treat briefly general information related to apheresis treatment [with-
out therapeutic plasma exchange (TPE)] with specific emphasis upon cytoreductive 
potential or thrombocytodepletion using cytapheresis treatment and lastly with 
presentation of our own results using TP procedures by comparison of the effi-
ciency of different generations and types of blood cell separators.
While practically all details on the ultrastructure of Plts are already identified 
and explained, some morphological and functional properties of these blood 
elements will be very concisely recapitulated. Therefore, prior to presenting of 
our own data of Plt fundamental researches and in clinical study setting, some 
elementary morphological/ultrastructural and functional characteristics of Plts will 
be given.
2. Apheresis/cytapheresis: a systematic overview
Apheresis or hemapheresis is a “hemomodulatory” procedure in which blood 
components (cells or plasma) are collected from donors (the so-called apheresis 
donation) or specific quantitatively or qualitatively altered constituents/factors 
are removed from the bloodstream, while the remainder (seldom combined with 
normal blood cells) is returned to the patient’s circulation (named as TAph) [1–4].
The basic goal of TAph procedures is to reduce the “patient’s load” of specific 
substances, responsible for the development of disease, to the levels that will allow 
clinical improvement [4–6]. TAph treatment should be done regularly or always 
combined with “immunomodulatory” (e.g., immunochemotherapy) and other 
palliative (drug) therapies. Based upon the criterion of what is the removed blood 
constituent—with specific “pathogenic factors or substrate”—it is possible to clas-
sify the TAph procedures into TPE and therapeutic cytapheresis (TC) [5–15].
TPE is a replacement of the patient’s plasma with an adequate substitution fluid 
(albumin in saline) or with normal (allogeneic) or modified (immunoadsorbed 
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autologous) plasma. The use of “selective” TPE results in reduced risk of side effects 
(immunomodulation or virus transmission) since “purified” autologous plasma is 
used as a replacement fluid [11, 12].
TC is an effective “disease-modifying” therapeutic approach in which elevated 
or altered cells are removed from the blood, while the residue is returned into the 
circulation. The basic goal of the evidence-based TC procedure is a reduction of 
the “patient’s load” with overproduced cell quantity or functionally altered cells, 
responsible for disease development [16–18]. TC procedures combined with immu-
nochemotherapy and other medications result in “hemobiological” and overall 
clinical recovery. Thus, the main objective of TC procedures (symptomatic or 
prophylactic) is to reduce the patient’s excessive cellular count—ex vivo Plt removal 
with in vivo Plt depletion (Plt removal/depletion)—and to alleviate symptoms 
created by these cells [1, 2, 18].
The goal of novel TC procedures—such as photopheresis, granulocyte adsorp-
tive apheresis, and RBC exchange (RBCX)—is the substitution of abnormal or 
“disease-responsible” cells, as well as ex vivo modification of “immunocompetent 
cells” prior to reinfusion, getting frequently long-term beneficial clinical effects. 
RBCX procedures are indicated for treatment of patients with irregular RBCs and 
consecutive hemorheological abnormality with anemia and other hemobiological 
disturbances [6, 7, 16].
Using standard TC procedures, the excessive cellular quantity is removed from 
the patient’s bloodstream with intention to reduce total blood cell count in organism 
and to prevent the symptoms and signs caused by various “cytemias.” According to 
blood cells removed, TCs can be categorized into therapeutic leukapheresis (TL), 
erythrocytapheresis (TE), and TP [6, 16–18].
The aim of TLs is white blood cell (WBC) count reduction and reverse of the 
“hyperleukocytosis-leukostasis” syndrome, regression of organomegaly and 
lymphadenomegaly, and improvement in general clinical status [2, 15–17]. TLs rep-
resent a useful “cytoreductive” therapy during “leukostasis crisis” when the number 
of circulating WBC ≥ 150 × 109/L. In the treatment of patients with excessive 
number (500 × 109/L or more) of leukemic cells, their removal by TL would have 
been adequate for “partial excision” of tumor mass even 1000–1500 g of “total cell 
mass” in removed cell suspension—that is in the apheresis product (AphP) [7, 17].
The objective of TE treatment is to obtain a hemorheological advance. Besides 
removal of the excess of RBCs from patient’s circulation, with TE it is possible to 
achieve hematological and hemorheological recovery (cellular hyperviscosity reduc-
tion) with consecutive improvement of tissue perfusion and oxygenation [2, 17].
Thrombocytapheresis or TP is useful in the treatment of patients with thrombo-
cythemia and symptomatic thrombocytosis until chemotherapy, antiplatelet drugs, 
and other medications takes effect. The purpose of TP might be determined as a 
method for rapid reestablishment of Plt overproduction, following prevention of 
“thrombo-hemorrhagic” events. Thromboembolism is more frequent than bleeding 
crisis, and the arterial thromboses (followed by cerebrovascular, coronary, or other 
occlusive episodes) happen more often than venous events [17–22].
The use of TP treatment is indicated when the Plt number ≥1500 × 109/L 
(“hyperthrombocytosis” or “extreme thrombocytosis”), although the degree of 
thrombocytosis and the complexity of clinical status are not always causally associ-
ated. However, Plt quantification is undoubtedly helpful in predicting patient’s 
hemostatic risk [22–29]. The details of TP treatment will be presented and discussed 
further below.
Concisely, the goal of our original and innovative “multi-manner” TAph is to 
offer the possibility of rapid returning from a “life-threatening” (irreversible) 
emergency—altering simultaneously more than one blood constituent(s)—to the 
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“district” of unbalanced, but reversible clinical condition, with a possibility for 
recovery of patient’s hematological and overall clinical homeostasis [13–15].
It is important to highlight and emphasize that TAph is an aggressive method, 
by which there is a direct intervention in patient’s circulation; therefore it might be 
followed by side effects and complications. In order to minimize them, different cri-
teria for selection of blood component donors and patients have to be applied. The 
analysis of laboratory parameters (blood cell count and biochemistry examination, 
screening testing for coagulation, etc.) is required too, along with clinical follow-up 
of the patients for which the TAph treatment is predicted.
The use of TAph procedures is not possible without (1) updated personal knowl-
edge in hematology, immunology, biochemistry, and hemorheology; (2) rational-
ized education for treatment of acute “life-threatening” conditions; and (3) clinical 
experience related to working with extracorporeal circulation and cardiopulmonary 
reanimation. For that reason, TAph is applied only in medical centers with tertiary 
level of health protection and in countries with developed medical service.
3. Platelet morphology, ultrastructure, and functionality
Following contact with subendothelial structures at the sites of vascular injury, 
the “connecting” of Plts (adhesion) will occur in the presence of the von Willebrand 
factor (vWF). Then Plts are activated—a process which involves a number of “cell 
surface receptors” for agonists (ADP, thrombin, thromboxane A2 (TXA2), collagen, 
etc.), as well as specific signal transduction pathways. Activation process increases the 
intracellular concentration of calcium ions—by releasing from specific cytoskeleton 
structures and calcium influx across cell membrane. Elevated calcium concentration 
results in ultrastructural (morphological) and functional Plt alterations [17, 30–33].
After activation, Plts change their morphology—from discoid into spheri-
cal (seldom to dendritic) shapes—as a consequence of reorganization of the 
membrane-system and cytoskeleton network (“shape change reaction”). Specific 
granules are centralized intracellularly, and their contents are discharged into the 
open canalicular system and then to the outside of the cell (“releasing reaction”). 
The alteration in shape is the beginning of a series of reactions during Plt response 
to the action of agonists. Thus, discoid Plts transform into spherical or dendritic 
shapes, with pseudopod formation. These changes are practically prompt and do 
not require the presence of large amounts of extracellular calcium ions and fibrino-
gen. This “early” stage of Plt response is conditioned by polymerization of actin 
and by disconnecting of some marginal microtubule bonds. Elevated intracellular 
calcium concentration stimulates the phospholipase A2 (which releases arachidonic 
acid from membrane phospholipids). Arachidonic acid is then metabolized lastly 
into TXA2—a potent Plt activator [6, 31–37].
The “shape change reaction” allows the Plts to interact with one another 
(“clumping”) in the blood to form aggregates. Therefore, the phenomenon of 
the Plt aggregation involves sequences of “platelet-to-platelet” interactions. This 
process requires the presence of extracellular calcium ions, as well as fibrinogen, 
with very close Plt surface contact [18, 30–32].
In a few words, Plt ultrastructure consists of three structural/functional 
zones: “peripheral zone,” “sol-gel zone,” and “organelle zone,” as well as the 
“membrane-system.”
The “peripheral zone” is responsible for Plt integrity and adhesion/aggrega-
tion—mediated by receptors and ligands (agonists). This zone consists of glyco-
calyx (external region), cytoskeleton or submembrane area, and cell membrane. 
Also, it incorporates various absorbed coagulation factors and receptors for 
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thrombin, ADP, collagen, vWF, thrombospondin, TXA2, prostacyclin, fibrinogen, 
fibronectin, etc. [18, 31–33].
The “sol-gel zone” is a viscous cytoskeleton matrix, which contains an open 
canalicular system or microtubules, microfilaments, some vesicles, and secretory 
organelles. Microtubules support the membrane contractile cytoskeleton and 
maintain a discoid Plt shape. In the microfilaments actin, myosin, actomyosin, and 
other substances were detected. Actin microfilaments in the “sol-gel zone” form 
actin cytoskeleton (matrix for organelles), while actomyosin is responsible for Plt 
contraction and may promote granule secretion [6, 32–35].
The “organelle zone” includes alpha-granules, dense granules, and lysosomal 
granules, glycogen particles, mitochondria, and others. Alpha-granules (50–80 per 
Plt) consist of vWF, fibronectin, platelet factor 4, beta-thromboglobulin, throm-
bospondin, platelet-derived growth factor (PDGF), and fibrinogen. The dense 
granules (3–8 per Plt) include adenine nucleotides, serotonin, pyrophosphate, 
calcium, and magnesium ions. The lysosomal granules (up to 3 per Plt) contain acid 
hydrolases, cathepsin D and E, lysosomal-associated membrane protein (LAMP)-2 
and some lipolytic enzymes, and CD63. Finally, the mitochondria are also in the 
“organelle zone” and provide Plt energy requirements. They are also a deposit and 
an important discharger of calcium ions [17, 30–35].
The open canalicular system of “membrane-system” can be used for transport 
of some plasma components (e.g., fibrinogen) to alpha-granules and for release 
of granular contents following Plt activation. The dense tubular system operates 
as a depot of calcium ions, and it is active during Plt contractions. Prostaglandin 
synthesis is discovered in these systems also after Plt activation [6, 30–32].
Generally, investigation of Plt functions is important for diagnosis of pathologi-
cal conditions with qualitative Plt disorders—e.g., hemorrhage tendency or risk of 
interventional bleeding, especially in patients treated by antiplatelet drugs—also 
for determination of “storage lesions” (liquid-state conserved or cryopreserved 
cells), as well as for the establishment of the “critical threshold” for Plt supportive 
therapy [31–38].
Testing by Multiplate analyzer—a rapid assay of whole-blood impedance 
aggregometry—can be used to detect Plt dysfunction and for prediction of bleed-
ings and/or some thrombotic events, also to resolve a personalized antiplatelet 
therapy (including monitoring of the treatment efficacy too), as well as to reduce of 
Plt transfusion needs. However, this testing does not give information concerning 
the Plt “shape change reaction” and the reversibility of aggregation and conse-
quently cannot be used for diagnosis of some specific Plt function disorders [18]. 
The results of our own Plt functional examinations will be shown afterward.
In our initial cryobiological research studies [34–38], cells were investigated in 
the “buffy coat”-derived Plt concentrates (BC-PCs) intended for prophylactic or 
therapeutic transfusions. Recently, in our clinical study [18], Plts were evaluated 
before and following TP treatment in the peripheral blood of ET patients, as well as 
in the removed AphP.
In these studies, cells were quantified in the donors’ blood samples and also 
in BC-PC units, as well as in the peripheral blood of patient before vs. after TP 
procedures and in the AphP using flow cytometry by Advia 2120 counter (Bayer, 
Germany). Morphological properties of Plts were examined by phase-contrast 
microscope (Polyvar, Reichert-Jung, Austria). The value of morphological score of 
platelets (MSP) was determined according to the percentage of different platelet 
shapes. Numerical valuation used for Plt shapes is as follows: balloonized = 0; den-
dritic = 1; spherical = 2; and discoid = 4. Ultrastructure of platelets was examined 
with electron microscope (Philips 201 C, Philips, The Netherlands). The Plt func-
tion by Multiplate analyzer (Dynabyte GmbH, Germany) was evaluated. Surface 
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Figure 1. 
Ultrastructure of Plts in cryobiological setting (our original data). Several discoid shapes had an unchanged 
“ultrastructural arrangement,” with minor membrane injuries (A). Spherical shapes showed an inferior 
“electron density” of the cytoskeleton, somewhat inferior cell structure compared to discoid shapes—which was 
manifested by marginal location of alpha-granules, dense granules, lysosomal granules, and other organelles 
in the cytoskeleton (B and C). Several dendritic shapes with reduced quantity of alpha granules, numerous 
pseudopodia, and unclear cell edges were also confirmed (D). Sporadic balloonized shapes with critical 
membrane damages and multiple ruptures, as well as fragments of the destroyed Plts, were also detected.
antigens were analyzed by flow cytometer Epics XL (Coulter, USA) using specific 
monoclonal antibodies [34–38].
Our preclinical studies [34–38] verified that in BC-PC units immediately after 
preparation (“unmanipulated” or unfrozen cells), the ratio of discoid shapes was 
about 60–80%, spherical approximately 15–25%, and functionally less valuable 
(dendritic or balloonized) shapes around 5–5%; then the value of MSP was between 
300 and 400. During storage, the incidence of discoid and spherical shapes progres-
sively decreased, while the less valuable ones increased. As a result, values of the 
MSP also reduced gradually. In BC-PC units stored in liquid state for up to 5 days, 
the MSP was approximately 200 [36].
The objective of our early cryobiological researches [34–42] was to determine an 
optimized cryopreservation protocol with minimized “thermal damages” (cryo-
injury) of frozen/thawed cells—retaining maximum quantitative (cell count) and 
qualitative (cell functionality, morphology, and ultrastructure) recovery. Different 
cryopreservation protocols with controlled-rate (“microprocessor-controlled”) or 
uncontrolled-rate (“dump-freezing” with no programmed cooling rate) freezing 
procedures, in combination with dimethyl sulfoxide (DMSO; final concentra-
tions = 5, 6, and 10%), were compared [34–38].
Preclinical researches demonstrated that the frequency of discoid shapes in all 
Plt cryopreservation settings was lower (range: 39–58%) than in “unmanipulated” 
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(unfrozen) BC-PC group [34]. It is also confirmed that controlled-rate freezing pro-
vides higher percentage of discoid and spherical shapes—with resultant superior 
MSP value. In the opposite, a higher proportion of functionally less valuable shapes 
(dendritic or balloonized) was observed in uncontrolled-rate cryopreservation 
setting [35].
Electron microscopy in our Plt cryopreservation researches [35–38] had shown 
the occurrence of different Plt types—mainly discoid and spherical, as well as 
sporadic dendritic or balloonized shapes (as presented in Figure 1).
Finally, in our recent clinical study [18], the “shape ratio” and ultrastructure of 
Plts in peripheral blood of ET patients with ETC (treated by TP) were also investi-
gated (Plt shapes are visualized in Figure 2).
A reduction of Plt function in patients with some disorders, also during liquid-
state storage or following cryopreservation, is usually caused by stated ultrastruc-
ture “rearrangement” or “reorganization.” The Plt membrane-system damage or 
destruction—with increased membrane permeability—can happen during the 
“phase change of the lipid.” Finally, the “disarrangement” of receptors on the Plt 
membrane results in interruption of signal transduction pathways during activation 
process.
Our clinical study [18] also confirmed that the baseline aggregability of Plts 
in the patient’s venous blood sample was 918 AU*min (normal = 923–1509 AU × 
min) by TRAP test (AU = aggregation unit; 10 AU × min is equal to one AUC [area 
under the curve] value; TRAP = thrombin receptor activating peptide). The results 
obtained indicated a merely Plt dysfunction (decreased activity) in the bloodstream 
of ET patient with ETC.
In our earlier research studies [34, 36–38] of “unmanipulated” and cryopre-
served BC-PCs, various surface antigens were analyzed by flow cytometry using 
Figure 2. 
Electron microscopy of Plt shapes in ET patient bloodstream (our own data). Discoid shapes had typical 
ultrastructural properties with intact microtubules and open canalicular system, without damage of the 
membrane-system integrity. Spherical shapes by peripheral location of granules/organelles in the cytoskeleton 
were also recognized (with resulting Plt dysfunction). A small number of dendritic shapes with cytoskeletal 
“rearrangement,” membrane-system damages and pseudopod formations were also recognized.
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monoclonal antibodies (MoAb) anti-GPIX/CD42a, anti-GPIIb-IIIa/CD41, anti-
GPIbα/CD42b, anti-GP140/P-selectin/CD62p, anti-GP53/CD63, and anti-GPIV/
CD36. Plts were incubated with fluorescein isothiocyanate or phycoerythrin-conju-
gated MoAb and then tested by flow cytometer.
Plts were evaluated on the basis of their characteristic cell size (“linear forward 
scatter”) and granularity (“log side scatter”) too [34]. Anionic phospholipid 
expression was tested using annexin V binding assay by flow cytometer. Cell viabil-
ity was assessed by the hypotonic shock response test [34–36]. In the supernatant 
of BC-PCs, the levels of transforming growth factor β (TGF-β), soluble P-selectin, 
soluble annexin, platelet factor 4 (PF4), and β-thromboglobulin (β-TG) were tested 
by enzyme-linked immunosorbent assays [34, 36].
These studies verified that the GPIb/CD42b expression was reduced in all cryo-
preserved BC-PC groups in opposition to “unmanipulated” or unfrozen (control) 
group [36, 37]. The expression of GP140/CD62p was in all cryopreservation groups 
higher than in control [36]. It was concluded that evaluation of expression of acti-
vation markers on Plt surface and flow cytometric analysis of Plt subpopulations 
could be a helpful approach for the quality control of liquid-stored or cryopreserved 
BC-PCs [34].
4. Thrombocythemia and therapeutic thrombocytapheresis
Before evaluation of cytapheresis cytoreductive efficacy in our studies—using 
different apheresis systems in critical “clinicopathological” conditions with ETC, 
in which apheresis is beneficial, required, or sometimes might result in rescue of 
patient with acute “life-threatening” hazardous situations—common thrombocyto-
sis-related data will be summarized.
4.1 Symptomatic thrombocytosis and thrombocythemia
The “critical threshold” for clinical significance of increased Plt count is variable 
from patient to patient—but, usually, conditions with Plt ≥450 × 109/L is designated 
as thrombocytosis. If thrombocytosis—typically with Plts ≥1500 × 109/L—appears 
within different myeloproliferative disorders, regularly we would talk about essen-
tial thrombocythemia (ET) [43–47].
Therefore, conditions with thrombocytosis and/or ETC can be classified into 
(1) primary disorder or ET, which is the consequence of clonal disease of the 
pluripotent hematopoietic stem cell, and (2) reactive or secondary thrombocy-
toses, which might evolve within patients with malignancies, chronic inflamma-
tory processes, after splenectomy, etc. The existence of ETC induces an acquired 
“thrombo-hemorrhagic” diathesis, occasionally with potentially fatal vascular 
consequences [23–29, 43–50].
The entity and nature of ET is like polycythemia vera (PV), primary myelofibro-
sis (PMF), and myeloproliferative neoplasm (MPN) [46]. Due to the disease course, 
some patients with ET or PV might progress into a PMF-like post-ET or post-PV 
myelofibrosis [47]. Namely, all three MPN share three commonly exclusive “driver” 
mutations: JAK2, CALR, and MPL3. The most frequent is JAK2V617F, which origi-
nates in approximately 99% of patients with PV, 55% with ET, and 65% with PMF 
[48]. Concerning other driver mutations, 15–30% patients are CALR mutated, and 
4–8% are MPL mutated, while 10–20% of the patients might not express any one of 
the three mutations, so they can be triple-negative [49].
Hemostatic mechanisms, by which thrombocytosis lead to “thrombo-hemor-
rhagic” events, are not completely explained. Different hemostatic defects and 
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cell abnormalities are described—such as altered Plt aggregability, intracellular 
accumulation of specific active substances, decreased activity of cofactors von 
Willebrand ristocetin and multimers of vWF with high molecular mass, etc. 
Diagnosis of thrombocythemia is established on the basis of the existence of the 
following criteria of the World Health Organization (WHO): (1) persistent Plt 
count ≥450 × 109/L in the blood; (2) the presence of one of the three mentioned 
driver mutations or in their absence the exclusion of other causes of thrombocytosis 
(reactive and clonal); and (3) bone marrow morphologic evaluation, especially for 
discriminating ET from pre-fibrotic PMF and “masked” PV [50].
In ET or with difficult cases of secondary or reactive thrombocytosis (some 
carcinomas or asplenia), characteristic manifestations are headaches, vertigo, 
transitory visual disturbances, modest or intense chest or abdomen pain, as well as 
acrocyanosis, paresthesia, and other disturbances (e.g., priapism). In these patients, 
it is common manifestation of “thrombo-hemorrhagic” syndrome—thrombosis, 
with successive hemorrhages (epistaxis and other minor bleedings), as well as 
increased occurrence of first trimester miscarriage. However, in thrombocytosis or 
thrombocythemia, it is not undoubtedly proven that there is a correlation between 
the degree of increased Plt count and complexity of patients’ clinical condition.
In therapy of ET patients, the main reason for treatment is to prevent “thrombo-
hemorrhagic” episodes, and from this point of view, none of the most recent drugs 
have been shown to be superior among the traditional drugs, such as hydroxyurea. 
Three major risk factors for thrombosis are history of thrombotic events, JAK2/
MPL mutations, and advanced age. In order to classify of ET patients—according to 
risk factors—there are four categories: “very-low-risk” (absence of all risk factors); 
“low-risk” (presence of JAK2/MPL mutations); “intermediate-risk” (presence of 
advanced age ≥60 years); and “high-risk” (presence of thrombotic events or occur-
rence of both JAK2/MPL mutations and advanced age) [48].
Patients with “very low risk” can be only observed or can take once-daily aspirin, 
while patients with “low-risk” disease take once- or twice-daily aspirin. In interme-
diate-risk setting, hydroxyurea and once-daily aspirin is therapy of choice, while in 
“high-risk” disease with arterial thrombosis, hydroxyurea and twice-daily aspirin is 
standard therapy. High-risk patients with venous thrombosis take hydroxyurea plus 
systemic anticoagulation, and when the JAK2/MPL mutation or cardiovascular risk 
factors are present, addition of aspirin is needed. Thus, therapy of these disorders 
includes the application of chemotherapy, antiaggregation, and other medications, 
as well as the use of TP procedures, when rapid reduction in Plt count is urgently 
needed (apheresis Plt depletion). Hydroxyurea is considered the drug of the first 
line for “medicamentous cytoreductive therapy.” Second-line therapeutic drugs are 
pegylated interferon-α (IFN-α), busulfan, anagrelide, and pipobroman [48].
4.2 Therapeutic thrombocytapheresis
Generally, in ET patients by ETC (Plt ≥ 1500 × 109/L) and with altered Plt 
morphology/aggregability (Plt dysfunction) and immature reticulated Plts, the risk 
of “thrombo-hemorrhagic” event incidence is enlarged up to 50–60% [18, 22].
In the treatment of symptomatic ET—when low-dose aspirin or other antiplatelet 
and high-dose chemotherapies are without adequate response or contraindicated, 
as in pregnancy—cytoreduction by TP is beneficial or even essential [1, 2, 51]. 
The evidence-based clinical guideline for therapy of asymptomatic ET (e.g., exact 
cytapheresis threshold, initial and target Plt count, etc.) is not yet established. 
The treatment of ET in pregnancy is still mainly individualized [51]. The first TC 
procedure in our apheresis center was performed in 1971 for treatment of pregnant 
women with “hyperleukocytosis-leukostasis” syndrome [17].
Platelets
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Generally, the most critical step in TC therapy of patients with different types of 
“cythemia” (blood cell overproduction) is to define the optimal timing, frequency, 
as well as the intensity and duration of treatment. The use of TC procedures 
requires determination of excessive cell category and total cell quantity and to 
resolve also the predominant cell divisions (including intravascular vs. extravascu-
lar portions), as well as to establish and compensate for “peri-apheresis” intensity 
of novel blood cell production [15–17].
The goal of TP (in combination with described medication) in therapy of ET 
patients with clinical symptoms is to minimize of consequences of ETC. TC proce-
dures performed using various devices (blood cell separators) operate in a wholly 
automatic manner—thus allowing “intra-apheresis” cell recruitment or refreshment 
and also minimizing the manual or individual (physician) variations and differ-
ences during treatment [16–18].
Therefore, TP procedures are used to obtain an effective and rapid cytoreduc-
tion in patients with ETC, in order to prevent or reduce “thrombo-hemorrhagic” 
events. The application of TP could be a life-saving procedure for selected ET 
patients with “life-threatening” clinical situation—due to acute episode of ETC. 
This treatment results in a dramatic Plt count fall and following clinical improve-
ment [2, 22, 43–45]. As well, TC procedures are helpful in the treatment of patients 
with symptomatic reactive or secondary thrombocytosis (all together with correc-
tion of the cause of ETC).
However, the definitive decision to apply of TP treatment should be “individual-
ized” on the basis of clinical scenario and intensity of ETC, as well as patients’ risk 
profile [29]. In this context, the efficacy of TP is dependent on the initial Plt count, 
kinetics of cell production, and the volume of whole blood processed, but also on 
the efficacy of different apheresis devices.
In our clinical settings [8, 16–18], typically antecubital (seldom subclavian or 
jugular) veins were used for vascular access. During TP procedures patients were 
anticoagulated by acid-citrate-dextrose formula B solution (ACD-B; USP; with 1.8% 
citrate concentration) or ACD-A solution (ACD-A; USP; with 2.2% citrate concen-
tration). A systemic heparinization was performed only in singular TP procedures. 
All patients tolerated intensive TP treatments well without any adverse effects.
The aim of our latest clinical study [18] was to evaluate the cytoreductive 
potential of the Spectra Optia/IDL System, based upon ex vivo Plt removal and in 
vivo Plt depletion (Plt removal/depletion) efficacy in the treatment of a 68-year-old 
female patient suffering from symptomatic ET (with headaches, vertigo, visual 
disturbances, and paresthesia). Modifications of manufacturer’s original apheresis 
protocol included the collection preference and inlet flow correction (altered 
collection speed), as well as an increase of the “target cell suspension” volume [18]. 
Plt removal/depletion efficacy obtained in this study was compared to our earlier 
results (historical database) [8, 17] and the recent literature data [23–25] for differ-
ent devices.
To the best of our knowledge, our clinical study [18] was only the second pub-
lished clinical evaluation of the efficacy and safety of TP treatment using Spectra 
Optia/IDL System.
In earlier studies [8, 17], using apheresis devices of the first and the second 
generations (Haemonetics M-30, IBM 2997, and Cobe Spectra), TP procedures 
were performed typically every second day (rarely every day)—combined with 
standard immunochemotherapy and other medications. Namely, in the treatment 
of our comparable ET patients (n = 20; procedures = 126; historical database), 
applying mentioned apheresis devices, by one single TP procedure, it was pos-
sible to remove approximately 3 × 1012 Plt/L in cell suspension approximately 
11
Rapid Cytoreduction by Plateletapheresis in the Treatment of Thrombocythemia
DOI: http://dx.doi.org/10.5772/intechopen.93158
800–1300 mL or total 7–10 × 1012 Plts by one “whole therapeutic cure” (typically 5 
single TPs; range = 3–11).
Opposite, in the treatment of recent ET patient with ETC-associated clinical 
emergency—using apheresis device of the newest generation and an intensive single 
TP treatment—the quantity of removed Plts was 7.5 × 1012 in the cell suspension 
(volume = 1150 mL) [18]. As replacement fluid, albumin in saline was used. There 
were no side effects due to intensive TP. Consequently, by Spectra Optia/IDL System 
using one TP, it was possible achieve similar therapeutic effect to that one which 
was realized after the application of “whole therapeutic cure” with devices of earlier 
generations.
In Cobe Spectra group (historical database) of our patients [17], the in vivo Plt 
depletion was approximately threefold lower. Only the use of “whole therapeutic 
cure” resulted in a satisfactory in vivo Plt fall (mean = 68 ± 14%; range = 55–85%). 
Recent literature data [28] are comparable—precisely, a 67% decrease in circulat-
ing Plt count (1553 × 109–513 × 109/L) was reported, but after two TP procedures. 
Contrary to our recent study [18], a significant Plt count depletion (from 2330 × 109 
to 633 × 109/L) and excellent in vivo Plt fall (72.8%) were realized by one single TP 
procedure—followed by clinical advances and prevention of potential “thrombo-
hemorrhagic” events (e.g., cerebrovascular accident—stroke).
The in vivo Plt depletion intensity in our current study (72.8%) was also supe-
rior among the most recent literature data [23–25]. Exactly, using a single TP by 
different apheresis devices, such as Haemonetics-MCS+ (therapy of low-body-mass 
child; Plts = 3072 × 109/L) [52], CS-3000 Plus and Cobe Spectra (management of 
hemato-oncological patients) [25], as well as Spectra Optia apheresis system (treat-
ment of ET patient; manufacturer’s protocol used) [24], the post-apheresis reduc-
tions of in vivo Plt depletion averaged only 37, 38, and 56%, respectively.
5. Conclusion
The purpose of TAph treatment is to reduce the “patient’s load” of specific 
substances, responsible for the development/progress of disease, to the levels that 
will allow clinical recovery. Using TC procedures, the excessive cellular quantity 
is removed from the patient’s bloodstream with the intention to reduce total blood 
cell count in the body and to prevent the symptoms caused by various “cytemias.” 
TAph is an aggressive method; therefore it might be followed by side effects and 
complications. Thus, the use of TAph procedures is not possible without personal 
education for treatment of acute “life-threatening” conditions, as well as clinical 
experience related to working with extracorporeal circulation and cardiopulmonary 
reanimation.
After activation, Plts change their morphology—from discoid into spheri-
cal (seldom to dendritic) shapes—as a consequence of reorganization of the 
membrane-system and cytoskeleton network (“shape change reaction”). Specific 
granules are centralized intracellularly, and their contents are discharged into the 
open canalicular system and then to the outside of the cell (“releasing reaction”). 
The alteration in shape represents the beginning of a series of reactions during Plt 
response to the action of agonists. Investigation of Plt functions is important for 
diagnosis of pathological conditions with qualitative Plt disorders—e.g., hemor-
rhage tendency or risk of interventional bleeding, especially in patients treated by 
antiplatelet drugs— and also for determination of “storage lesions” (liquid-state 
conserved or cryopreserved cells), as well as for the establishment of the “critical 
threshold” for Plt supportive therapy. The evaluation of membrane antigens and 
Platelets
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flow cytometric analysis of Plt subpopulations could be helpful for the quality 
control of stored BC-PCs.
Based on the literature data and our own results, it is possible to conclude that 
intensive TP is an effective and safe procedure—even in long-term application 
(repeated or intermittent procedures) over a period of a few weeks/months—for 
patients with ET or secondary thrombocytoses and “life-threatening” ETC.
The application of a single TP procedure in the treatment of recent ET patient by 
Spectra Optia/IDL System resulted in undoubtedly superior Plt removal/depletion 
efficacy (for both normal and altered cells) when compared to our earlier study 
(Cobe Spectra) and literature data for CS-3000 Plus or Cobe Spectra, even for the 
Spectra Optia (when the manufacturer’s original protocol was used). Although TPs 
represent an effective cytoreductive therapy with high level of Plt removal/deple-
tion potential, it cannot influence clinical remission.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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